Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Platinum-Resistant Nasopharyngeal Cancer
2024-517479-19-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in nasopharyngeal carcinoma (NPC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoint: Objective response rate at 12 weeks. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2024-517479-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517479-19-00.